Clin2
NCT07770100Likely a fitNot yet recruiting

Immunotherapy plus targeted radiation for advanced cancer

Head and Neck CancerNon-Small Cell Lung CancerCervical CancerEsophageal CancerGastric Cancer (GC)

Treatments studied

Part of Cancer, Digestive system, Lungs & breathing, Women’s health & pregnancy clinical trials.

This study tests whether combining immunotherapy (which boosts your immune system) with a precise, high-dose radiation treatment called SBRT can help people with advanced cancer live longer. It is for patients with at least 6 tumors that have spread, and aims to see if this treatment shrinks tumors and is safe.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
35 people
Ages
18 years to 99 years
Study type
Interventional

Who can take part

  • You have advanced or stage IV cancer of the head, neck, lung, cervix, stomach, or esophagus.
  • You have at least 6 tumors that have spread to other parts of the body (e.g., lung, liver, bone, or lymph nodes).
  • You are eligible for immunotherapy (a type of treatment that helps your immune system fight cancer).
  • You have not had chemotherapy or radiation within the last 21 days (unless it was for brain tumors, then you can start sooner).
  • You are generally able to do daily activities (performance status 0 or 1).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07213934Recruiting· Phase 1/Phase 2
Immunotherapy and radiation before surgery for recurrent head and neck cancer

This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.

Cincinnati, Ohio
NCT07603856Recruiting· Phase 2
Combining Immunotherapy and Radiation for Advanced Lung Cancer

This study tests whether adding focused radiation therapy to immunotherapy can help patients with advanced non-small cell lung cancer whose cancer has progressed despite prior immunotherapy. The goal is to see if this combination works better than immunotherapy alone.

Chicago, Illinois
NCT06686771Recruiting· Phase 3
Radiation for limited growth in advanced lung cancer on immunotherapy

This trial tests whether giving high-precision radiation to a few spots that are growing during immunotherapy (with or without chemotherapy) can help people with advanced lung cancer. It aims to see if treating these limited areas of resistance can extend the time the cancer stays under control.

Phoenix, Arizona
NCT07554768Not yet recruiting· Phase 2
Radiation plus immunotherapy for advanced head and neck cancer

This trial tests whether combining radiation therapy with immunotherapy works better than immunotherapy alone for advanced head and neck cancer that hasn't been treated before. The goal is to help your body's immune system fight the cancer more effectively.

Guangzhou, Guangdong
NCT06306846Recruiting· Phase 2
Radiation and immunotherapy before surgery for head and neck cancer

This study tests giving a short course of targeted radiation (SBRT) along with immunotherapy and a targeted drug before surgery for advanced head and neck cancer. The goal is to see if this combination can shrink the tumor and improve outcomes.

Hangzhou, Zhejiang
NCT05754203Recruiting
Radiation plus immunotherapy for advanced lung cancer

This trial studies whether a more intensive form of targeted radiation, combined with immunotherapy (immune checkpoint inhibitors), can work better and be safe for people with advanced non-small cell lung cancer. You may be considered if your tumor is limited in size and you’re able to receive both treatments.

Chongqing, Chongqing Municipality

Hear when a new Head and Neck Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.